glutamine has been researched along with canagliflozin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beneke, S; Delp, J; Dietrich, DR; Gutbier, S; Leist, M; Schlichenmaier, N; Secker, PF | 1 |
| Cai, W; Chen, Z; Ding, Y; Jiang, H; Song, X; Wu, X; Xu, J; Xu, Q; Ying, H; Ying, K; Yu, F; Zeng, L; Zeng, Y; Zhang, X; Zhao, L; Zhou, R | 1 |
2 other study(ies) available for glutamine and canagliflozin
| Article | Year |
|---|---|
Canagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
Topics: Alanine; Benzhydryl Compounds; Canagliflozin; Cell Death; Cell Line; Citric Acid Cycle; Electron Transport Complex I; Epithelial Cells; Glucosides; Glutamate Dehydrogenase; Glutamic Acid; Glutamine; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Metabolomics; Mitochondria | 2018 |
Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation.
Topics: Canagliflozin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glutamine; Glycolysis; Humans; Liver Neoplasms; Proto-Oncogene Proteins c-myc; Thyroid Hormone-Binding Proteins | 2023 |